Approval · Notice of Compliance 32314 · 2023
DANTRIUM CAPSULES: Notice of Compliance 32314
Issued December 8, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32314
- Date
- December 8, 2023
- Company
- Endo Par Innovation Company, LlcChestnut Ridge, New York, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DANTRIUM CAPSULES | Not yet assigned | — |
Medicinal ingredients
- DANTROLENE SODIUM 25 MG per CAP